# A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

> **NCT03761407** · PHASE1 · COMPLETED · sponsor: **Grünenthal GmbH** · enrollment: 48 (actual)

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** 100 mg GRT0151Y
- **DRUG:** 125 mg GRT0151Y
- **DRUG:** 150 mg GRT0151Y
- **DRUG:** 225 mg GRT0151Y
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT03761407
- **Lead sponsor:** Grünenthal GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12-30
- **Primary completion:** 2005-07-26
- **Final completion:** 2005-07-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03761407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03761407, "A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03761407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*